Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Ofatumumab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Pegfilgrastim; Prednisone; Vincristine
- Indications Burkitt's lymphoma; Leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 10 May 2019 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 15 Mar 2019 Planned End Date changed from 1 Jan 2019 to 31 Dec 2022.
- 15 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 31 Dec 2022.